Drug Trial Radar · NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
199
Planned (sponsor's estimate)
Start
Jul 15, 2021
Primary completion
Nov 17, 2023
Study completion Mar 29, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.
Conditions
- Myasthenia Gravis
Interventions
NipocalimabDrug
Nipocalimab will be administered as an IV infusion.
PlaceboDrug
Matching placebo will be administered as an IV infusion.
Nipocalimab SC-LIVDrug
Nipocalimab will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24Time frame: Baseline, Weeks 22, 23, and 24
- Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
- Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
Locations
112 sites in 17 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center and Clinic
Paradise Valley, Arizona · Recruiting
HonorHealth Neurology
Scottsdale, Arizona · Completed
University of Southern California
Los Angeles, California · Completed
Stanford University
Palo Alto, California · Completed
Care Access Research
Pasadena, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Yale New Haven Hospital
New Haven, Connecticut · Recruiting
FM Clinical Research, LLC South Florida Neurology Associates, P. A.
Boca Raton, Florida · Recruiting
University of Florida Health Jacksonville
Jacksonville, Florida · Completed
Medsol Clinical Research Center Inc
Port Charlotte, Florida · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Augusta University
Augusta, Georgia · Completed
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
St. Elizabeth Medical Center
Boston, Massachusetts · Completed
Lahey Hospital & Medical Center
Burlington, Massachusetts · Completed
Washington University School Of Medicine
St Louis, Missouri · Completed
Duke University School of Medicine
Durham, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Completed
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Completed
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Wesley Neurology
Cordova, Tennessee · Completed
UT Southwestern Medical Center
Dallas, Texas · Completed
University of Vermont
Burlington, Vermont · Completed
Melbourne Neurology Group
North Melbourne, Australia · Completed
Gold Coast University Hospital
Southport, Australia · Recruiting
ULB Hôpital Erasme
Anderlecht, Belgium · Recruiting
AZ Sint Jan Brugge Oostende AV
Bruges, Belgium · Recruiting
Cliniques Universitaires Saint Luc
Brussels, Belgium · Recruiting
AZ Sint-Lucas
Ghent, Belgium · Recruiting
University Hospitals Leuven
Leuven, Belgium · Recruiting
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
McGill University
Montreal, Quebec, Canada · Completed
Beijing Tiantan Hospital, Capital Medical University
Beijing, China · Recruiting
Xuanwu Hospital ,Capital Medical University
Beijing, China · Completed
Beijing Hospital
Beijing, China · Recruiting
The First Bethune Hospital of Jilin University
Changchun, China · Recruiting
Xiangya Hospital Central South University
Changsha, China · Recruiting
West China Hospital of Sichuan University
Chengdu, China · Completed
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.